

3 September 2010

The Manager  
Company Announcements Office  
ASX Limited  
20 Bridge St  
SYDNEY NSW 2000

- **CBio announces full recruitment of 150 patients into the Rheumatoid Arthritis clinical trial of XToll®**
- **Accelerated recruitment strategy sees milestone achieved four weeks ahead of schedule**

BRISBANE, 3 September 2010: Australian drug development company CBio Limited (ASX: CBZ) today announced full recruitment into the phase II clinical trial of the company's lead product XToll®, a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis.

Accelerated recruitment strategies, which included the opening of clinical trial sites in Central and Eastern Europe in addition to existing Australian and New Zealand sites, have achieved full recruitment into the 150 patient study four weeks ahead of schedule.

CBio Managing Director Jason Yeates said he was pleased with the company's progress.

"The CBio team has worked tirelessly to complete recruitment in the shortest possible timeframe since opening new clinical trial sites in Europe and I am pleased to announce today that we have reached our recruitment milestone of 150 patients into the trial," Mr Yeates said.

"Achieving full recruitment early allows us to receive completed clinical reports ahead of schedule which allows us to provide these reports and the clinical trial data to multinational pharmaceutical companies earlier than expected," he said.

"The company has made significant progress on all its activities since listing on the ASX in February this year. We have the pending issue of one of the core patents for XToll® in Europe and we continue to progress discussions with an Australian-based contract manufacturing organisation for our future clinical trial product needs. We are well placed to complete the critical activities on time as outlined in our IPO prospectus," Mr Yeates said.

"The Board and I remain confident in XToll®'s medicinal and commercial potential." Mr Yeates said.

#### COMPANY & INVESTOR RELATIONS

Ben Graham  
Company Secretary  
CBio Limited  
T: +61 7 3841 4844  
[ben.graham@cbio.com.au](mailto:ben.graham@cbio.com.au)

#### MEDIA LIAISON

Melanie Farris  
Manager, Corporate Projects  
CBio Limited  
T: +61 449 148 448  
[melanie.farris@cbio.com.au](mailto:melanie.farris@cbio.com.au)

#### **About CBio**

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll® is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis. It is currently being trialed in phase II clinical trials in patients with rheumatoid arthritis (RA). Global sales of RA therapies exceeded US\$17 billion in 2008.

Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll®.

CBio's Board includes internationally experienced drug developers including Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).

#### **About Rheumatoid Arthritis**

Rheumatoid Arthritis is a chronic autoimmune disease, mainly characterised by inflammation of the lining of the joints. It can lead to long-term joint damage, resulting in chronic pain, loss of function and disability. The effects of RA are systemic, which means it can affect other organs in the body, and cardiovascular dysfunction in addition to RA is common. RA symptoms can make even the simplest activities – such as opening a jar or taking a walk – difficult to manage. RA has a worldwide distribution with a prevalence of 1 to 2% – which currently equates to approximately 100 million people. Prevalence increases with age, approaching 5% in women over age 55. RA is two to three times more common in women than in men and generally occurs between the ages of 40 and 60, but it can also affect young children and older adults. Currently, there is no cure.